GGrantIndex
← Leaderboards

Gregory S Martin

Emory University

$5,670,342
Attributed
$7,726,925
Total exposure
8
Grants
6
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $50.9M · FY200825
$100M$75M$50M$25M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$99,652,198 · 8
FDA$1,050,000 · 1

By mechanism

U54$94,750,534 · 4
UM1$2,505,428 · 1
P50$1,407,391 · 1
R01$1,050,000 · 1
K23$633,820 · 1
R21$355,025 · 1

Top collaborators

Most similar at Emory University

Same institution · by research overlap

Others in their field

Top investigators on “Programs

Research focus

ProgramsTranslationsClinical ResearchLungBaseEngineeringMicrosystemsResearch Clinical TestingHuman SubjectValidationAdoptionUniversity HospitalsCountryTechnologyHospitalsLung DiseasesDevicesUnited States National Institutes Of HealthChild Health CarePrototypePediatric HospitalsDiagnosticElectronicsInnovation

Grant awards (41)

Atlanta Center for Microsystems Engineered Point-of-Care Technologies (ACME POCT)$1,561,849
U54 · FY2025 · EB
Clinical Core$237,186
U54 · FY2025 · EB · contact PI
Atlanta Center for Microsystems Engineered Point-of-Care Technologies (ACME POCT)$1,561,849
U54 · FY2024 · EB
Clinical Core$237,186
U54 · FY2024 · EB · contact PI
Atlanta Center for Microsystems Engineered Point-of-Care Technologies (ACME POCT)$1,618,350
U54 · FY2023 · EB
Clinical Core$251,313
U54 · FY2023 · EB · contact PI
ACME POCT EMERGENCY COVID-19 VARIANT TESTING & INDEPENDENT TEST ASSESSMENT EVALUATION SUPPLEMENT$15,864,683
U54 · FY2022 · EB
Emergency COVID-19 Variant Supplement for Atlanta Center for Microsystems Engineered Point-of-Care Technologies (ACME POCT)$15,481,896
U54 · FY2022 · EB
Atlanta Center for Microsystems Engineered Point-of-Care Technologies (ACME POCT)$1,372,712
U54 · FY2022 · EB
Atlanta Center for Microsystems Engineered Point-of-Care Technologies (ACME POCT)$648,527
U54 · FY2022 · EB
Clinical Translation and Validation Core$226,356
U54 · FY2022 · EB · contact PI
Atlanta Center for Microsystems Engineered Point-of-Care Technologies (ACME POCT)$1,373,615
U54 · FY2021 · EB
Clinical Translation and Validation Core$205,805
U54 · FY2021 · EB · contact PI
Emergency COVID-19 supplement for Atlanta Center for Microsystems Engineered Point-of-Care Technoloites (ACME POCT)$31,080,737
U54 · FY2020 · EB
Atlanta Center for Microsystems Engineered Point-of-Care Technologies (ACME POCT)$11,194,205
U54 · FY2020 · EB
Atlanta Center for Microsystems Engineered Point-of-Care Technologies (ACME POCT)$7,085,000
U54 · FY2020 · EB
Atlanta Center for Microsystems Engineered Point-of-Care Technologies (ACME POCT)$1,374,470
U54 · FY2020 · EB
Clinical Translation and Validation Core$205,805
U54 · FY2020 · EB · contact PI
Atlanta Center for Microsystems Engineered Point-of-Care Technologies (ACME POCT)$1,376,145
U54 · FY2019 · EB
Clinical Translation and Validation Core$205,805
U54 · FY2019 · EB · contact PI
Atlanta Center for Microsystems Engineered Point-of-Care Technologies (ACME POCT)$1,381,235
U54 · FY2018 · EB
Clinical Translation and Validation Core$205,805
U54 · FY2018 · HL · contact PI
Vitamin C Infusion for Treatment in Sepsis Induced Acute Lung Injury (CITRIS-ALI)$853,679
UM1 · FY2016 · HL
Vitamin C Infusion for Treatment in Sepsis Induced Acute Lung Injury (CITRIS-ALI)$881,978
UM1 · FY2014 · HL
Vitamin C Infusion for Treatment in Sepsis Induced Acute Lung Injury (CITRIS-ALI)$769,771
UM1 · FY2013 · HL
Phase III Study Comparing Albumin and Hetastarch Therapy in Acute Lung Injury$275,000
R01 · FY2013 · FD · contact PI
Clinical Core$238,781
P50 · FY2013 · AA · contact PI
Clinical Core$278,772
P50 · FY2012 · AA · contact PI
HIGH-DOSE VITAMIN D AND ANTIMICROBIAL PEPTIDE EXPRESSION IN LUNG FAILURE$193,650
R21 · FY2012 · HL · contact PI
Phase III Study Comparing Albumin and Hetastarch Therapy in Acute Lung Injury$75,000
R01 · FY2012 · FD · contact PI
Clinical Core$274,696
P50 · FY2011 · AA · contact PI
HIGH-DOSE VITAMIN D AND ANTIMICROBIAL PEPTIDE EXPRESSION IN LUNG FAILURE$161,375
R21 · FY2011 · HL · contact PI
Phase III Study Comparing Albumin and Hetastarch Therapy in Acute Lung Injury$350,000
R01 · FY2010 · FD · contact PI
Clinical Core$312,206
P50 · FY2010 · AA · contact PI
Clinical Core$302,936
P50 · FY2009 · AA · contact PI
Phase III Study Comparing Albumin and Hetastarch Therapy in Acute Lung Injury$350,000
R01 · FY2008 · FD · contact PI
ONCOTIC PRESSURE AND EXTRAVASCULAR LUNG WATER IN ARDS$127,220
K23 · FY2004 · HL
ONCOTIC PRESSURE AND EXTRAVASCULAR LUNG WATER IN ARDS$126,100
K23 · FY2003 · HL
ONCOTIC PRESSURE AND EXTRAVASCULAR LUNG WATER IN ARDS$125,905
K23 · FY2002 · HL
ONCOTIC PRESSURE AND EXTRAVASCULAR LUNG WATER IN ARDS$128,455
K23 · FY2001 · HL
ONCOTIC PRESSURE AND EXTRAVASCULAR LUNG WATER IN ARDS$126,140
K23 · FY2000 · HL